Despite widespread use of the Bacillus Calmette-Guerin vaccine, tuberculosis, caused by infection with , remains a leading cause of morbidity and mortality worldwide. As CD8 T cells are critical to tuberculosis host defense and a phase 2b vaccine trial of modified vaccinia Ankara expressing Ag85a that failed to demonstrate efficacy, also failed to induce a CD8 T cell response, an effective tuberculosis vaccine may need to induce CD8 T cells. However, little is known about CD8, as compared to CD4, antigens in tuberculosis. Herein, we report the results of the first ever HLA allele independent genome-wide CD8 antigen discovery program. Using CD8 T cells derived from humans with latent tuberculosis infection or tuberculosis and an interferon-γ ELISPOT assay, we screened a synthetic peptide library representing 10% of the proteome, selected to be enriched for antigens. We defined a set of immunodominant CD8 antigens including part or all of 74 proteins, only 16 of which are previously known CD8 antigens. Immunogenicity was associated with the degree of expression of mRNA and protein. Immunodominant antigens were enriched in cell wall proteins with preferential recognition of Esx protein family members, and within proteins comprising the secretome. A validation study of immunodominant antigens demonstrated that these antigens were strongly recognized in -infected individuals from a tuberculosis endemic region in Africa. The tuberculosis vaccine field will likely benefit from this greatly increased known repertoire of CD8 immunodominant antigens and definition of properties of proteins important for CD8 antigenicity.